Plain-English translation of NCT06083207 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a new medication called in people with multiple myeloma—a blood cancer of plasma cells in the bone marrow—that has come back or stopped responding to previous treatments. The trial has two main phases: first, researchers will carefully increase doses to find the safest and most effective dose of the medication; then, they will test how well that dose works in a larger group of patients.
Multiple myeloma can become resistant to standard treatments, and patients need new options. This trial exists to see whether this medication can help people whose cancer has stopped responding to earlier therapies.
You likely qualify if…
You likely don't qualify if…
You will receive the medication at a medical center as part of a carefully monitored treatment plan. In the first phase, the dose will be gradually increased across different patient groups to find the safest level; in the second phase, patients will receive the established dose while researchers track how well it works and monitor for side effects. You will have regular clinic visits, blood tests, and imaging scans to assess your response to the treatment.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
Australia
China